| Name | Title | Contact Details |
|---|
FMW operates a 50,000-square-foot manufacturing facility at the Mid-Atlantic Aerospace Complex at Benedum Airport.
Impulsum focuses on solving high value problems for people and companies that have the power to create a cultural shift for a more positive future. In addition to product innovation work with clients, Impulsum actively incubates new business concepts in collaboration with a diverse range of capital partners to develop market-leading companies that have the potential to become iconic household names. We specialize in complex product experiences and have deep expertise in social networks, eCommerce, digital consumer, secure communication technology, PCI/payments/issuance, and blockchain. Our team is spread across the globe and made up of individuals who have a passion for design, solving complex problems and building companies that make the world smile :)
Gigantic ArtSpace is a New York, NY-based company in the Business Services sector.
Housedna.com is a New York, NY-based company in the Business Services sector.
TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients own islet cell health.